Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response-Reference-Cited by-同舟云学术

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

Published:2021-02-08 Issue:7 Volume:81 Page:1667-1680
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Zhang Ping^ORCID,Kitchen-Smith Isaac,Xiong Lingyun^ORCID,Stracquadanio Giovanni,Brown Katherine,Richter Philipp H.,Wallace Marsha D.,Bond Elisabeth,Sahgal Natasha,Moore Samantha,Nornes Svanhild,De Val Sarah,Surakhy Mirvat^ORCID,Sims David,Wang Xuting,Bell Douglas A.,Zeron-Medina Jorge,Jiang Yanyan,Ryan Anderson J.^ORCID,Selfe Joanna L.,Shipley Janet,Kar Siddhartha,Pharoah Paul D.^ORCID,Loveday Chey^ORCID,Jansen Rick,Grochola Lukasz F.^ORCID,Palles Claire^ORCID,Protheroe Andrew,Millar Val,Ebner Daniel V.^ORCID,Pagadala Meghana^ORCID,Blagden Sarah P.^ORCID,Maughan Timothy S.^ORCID,Domingo Enric^ORCID,Tomlinson Ian^ORCID,Turnbull Clare,Carter Hannah^ORCID,Bond Gareth L.

Funder

Ludwig Institute for Cancer Research

Nuffield Department of Medicine

Oxford Cancer Research Centre

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: TP53 c.848G>A germline mutation as a possible screening target at initial diagnosis for acute lymphoblastic leukemia;Hematology;2024-07-15

2. Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants;Annals of Hematology;2024-05-14

3. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk;2024-03-04

4. The importance of protein domain mutations in cancer therapy;Heliyon;2024-03

5. Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG);Expert Opinion on Pharmacotherapy;2024-02-11